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Patients with decompensated liver cirrhosis have various serious complications which require multiple drugs for therapeutic or
prophylactic use. Majority of the drugs are primarily metabolized and excreted by hepatobiliary system; hence, liver cell necrosis
contributes to impaired drug handling in liver failure while portosystemic shunt can alter drug action in cirrhosis. Hence, in
order to decide drug dosing in liver failure, 3 important factors need to be considered (1) pharmacokinetic alterations of drugs,
(2) pharmacodynamic alteration of drugs, and (3) increased susceptibility of patients to adverse events particularly hepatotoxicity.
Though there is no predictable test which can be used to determine drug dosage in patients with decompensated liver cirrhosis,
drugswithﬁrstpassmetabolismrequirereductioninoraldosages,forhighclearancedrugsbothloadingandmaintenancedosages
need adjustment, for low clearance drugs maintenance dose needs adjustment, whenever possible measuring drug level in the
blood and monitoring of adverse events frequently should be done. No evidence-based guidelines exist for the use of medication
inpatients’withlivercirrhosis.Therearehardlyanyprospectivestudiesonthesafetyofdrugsincirrhoticpatients.Accordingtothe
experts opinion, most of the drugs can be used safely in patients with cirrhosis, but drug-induced hepatotoxicity may be poorly
tolerated by patients with cirrhosis; hence, potential hepatotoxins should be avoided in patients with liver cirrhosis. Potentially
hepatotoxic drugs may be used in patients with liver cirrhosis based on the clinical needs and when there are no alternatives
available. Caveat for the prescribing medications in patients with cirrhosis the drug dosing should be individualized depending
on a number of factors like nutritional status, renal function, adherence, and drug interaction. Monitoring of the liver function at
frequent intervals is highly recommended.
1.Introduction
Liver is a primary site of drug metabolism. Various steps in
the drug biotransformation in the liver are entry of the drug
in the liver, uptaken by the liver cells, phase I reaction,
for example, hydrolysis, hydroxylation, oxidation, reduction,
demethylation and phase II reactions conjugation with
glycine, glucuronide sulphate, hippurate, and others. These
steps are dependent on two factors, hepatic blood ﬂow
and metabolic capacity of the liver. In patients with liver
cirrhosis impaired drug handling is due to (1) liver cell
necrosis, (2) shunting of the blood through porta systemic
colaterals, (3) reduction in the concentration of drug-bind-
ing proteins, (4) abnormal drug volume distribution, (5)
altered drug elimination, (6) altered drug metabolism, (7)
altered pharmaco dynamics, (8) associated renal failure,
and (9) drug-drug interaction. The impairment of drug
metabolism is proportional to the liver dysfunction. Patients
with well-compensated cirrhosis and near-normal syn-
thetic function will have a lesser extent of impaired drug
metabolism as compared to patients with decompensated
cirrhosis with signiﬁcant synthetic dysfunction and portal
hypertension [1, 2]. Though various tests like liver function
test, indocyanine green clearance, megaxx, Child Pugh score,
and meld score are used for prediction of impaired liver
function, still no tests can determine drug dosing in these
patients. Drugs with ﬁrst pass metabolism require reduction
in oral dosages, for high clearance drugs both loading and
maintenance dosage need adjustment, for clearance drugs
maintenance dose needs adjustment (Figure 1). Whenever2 International Journal of Hepatology
Dose dependent
Adjust dosage
Consider plasma binding ++
Liver test baseline
Dose independent
No dosage adjustment
Consider pharmacodynamic eﬀects
Hepatic failure + potentially hepatotoxic antibiotics
Monitor clinical course and liver tests
Figure 1: Algorithm for drug dosing in liver failure. Possibly avoids drugs which are metabolized by liver and/or have potential hepatotoxi-
city.
possible, measuring drug level in the blood and monitoring
of adverse events frequently should be done. No evidence-
based guidelines exist for the use of medication in patients
with liver cirrhosis [3–5]. There are hardly any prospective
studies on the safety of drugs in cirrhotic patients. Drug-
induced liver injury (DILI) is the commonest cause of drug
withdrawal from further development and from the market
[6]. Almost 50% of the drugs are associated with some
sort of liver injury [7]. Nearly 100 drugs are known to
cause fulminant hepatic failure, and 10% of all adverse drug
reaction are hepatotoxicity [8, 9]. Approximately 1000 drugs
and several herbal remedies have been shown to be causing
DILI. Because of this drugs associated with liver toxicity are
usuallycontraindicated in patients with chronic liver disease;
still most of the drugs can be used safely in patients with
chronicliverdiseaseaccordingtotheexpertopinion[10–13].
According to the experts’ opinion most of the drugs can
be used safely in patients with cirrhosis, but drug-induced
hepatotoxicity may be poorly tolerated by patients with
cirrhosis; hence, potential hepatotoxins should be avoided
in patients with liver cirrhosis [14]. Potentially hepatotoxic
drugs may be used in patients with liver cirrhosis based
on the clinical needs and when there are no alternatives
available. Caveat for the prescribing medications in patients
with cirrhosis the drug dosing should be individualized
depending on a number of factors like nutritional status,
renal function, adherence, and drug-drug interaction. Mon-
itoring of the liver function at frequent intervals is highly
recommended [14, 15]. In spite of these recommendations,
monitoring of drug-induced liver injury by alanine transam-
inase is inconvenient and not followed by both patients and
physicians [4]. We as clinicians should educate our patients
about the warning signs of drug-induced liver injury like
abdominal pain, nausea, and jaundice for stopping the drugs
and seeking urgent medical attention.
In this paper after extensive literature search and expert
opinions, I will discuss rational use of various drugs in
patients with cirrhosis.
2.AntibioticDosinginCirrhosis
Liver is an important site of removal of blood bone bacteria.
Hepatic destruction of bacteria and reticular endothelial
Table 1: Antibiotics to be avoided in liver disease.
Chloramphenicol—higher risk of bone marrow suppression
(markedly increased half life)
Erythromycin estolate: causes cholestasis
Tetracycline—dose related hepatotoxicity
Antituberculous therapy in combinations, pyrazinamide
Griseofulvin—contraindicated
Nalidixic acid
Nitrofurantoin prolonged use
system-related phagocytosis are impaired in patients with
cirrhosis. In cirrhotic patients serum bactericidal opsonic
activity and neutrophil function are defective. This leads to
5 to 7 fold increase in bacteremia in these patients requiring
antibiotics for therapeutic or prophylactic purpose [16].
Extensive literature search was done to identify the antibi-
otics that need dosage alteration in patients with liver cirrho-
sis. Macrolide antibiotics like erythromycin, azithromycin,
chloramphenicol, lincomycine, and clindamycin which are
excreted and detoxiﬁed by liver should be used with cautions
in these patients. Tetracycline, Isoniazid and Rifampin have
prolonged half life in patients with liver cirrhosis. Metron-
idazole ketocanozole, miconazole, ﬂuconazole, itraconazole,
and nitrofurantoin pyrazinamide should be used with cau-
tion. Beta-lactum antibiotics can cause leucopenia, while
amino glycosides can increase susceptibility to renal failure.
Vancomycin can cause increased toxicity in patients with
liver failure. Antibiotics which can produce hepatitis or
cholestasis should be avoided or used with caution. Tuber-
culosis was more common in alcoholic and Child class C
cirrhosis (Table 1). Antituberculosis therapy (ATT) is asso-
ciated with hepatotoxicity in 10%. Hepatotoxicity requires
withdrawal, modiﬁcation, and sequential reintroduction to
achieve cure of tuberculosis. Using such hepatotoxic drugs in
presence of cirrhosis or advanced liver disease is a challenge.
Cirrhotic patients with tuberculosis have signiﬁcantly lower
completion of Rifamipicin + Isoniazid based ATT, higher
hepatotoxicity, and higher mortality. Recommended ATT in
Child class A cirrhosis is the same as a noncirrhotic popu-
lation but strict followup is required. Pyrazinamide may be
avoided. In Child class B Pyrazinamide should be avoided,International Journal of Hepatology 3
Table 2: Antibiotics which need to be used with extra caution in patients with liver failure.
Piperacillin Nalidixic acid Azithromycin
Ceftazidime Peﬂoxacin Tetracycline
Ceftriaxone Gatiﬂoxacin Cotrimoxazole + Trimethoprim
Cefoperazone Erythromycin Metronidazole
Cefoperazone + Sulbactam Cefetamet Roxithromycin Ketoconazole & other ﬂuconozoles
Table 3: Antibiotics causing hepatotoxicity.
Hepatocellular injury Cholestatic injury Fulminant hepatic failure
Chloramphenicol, Clindamycin Cephalosporins, Erythromycin Sulfonamides,
Trimethoprim—Sulfomethoxazole
Penicillin G, Amoxicillin Penicillin G, Oxacillin, Cloxacillin Ketoconazole, PAS, Trovaﬂoxacin
Trimethoprim—Sulfomethoxazole Floxacillin, Augmentin,
Clarithromycin
Amphotericin,
Hydroxystilbamidine
Nitrofurantoin,
Trimethoprim—Sulfomethoxazole
Ketoconazole, Itraconazole 5-ﬂuorocytosine, Griseofulvin
INH, Trovaﬂoxacin, Oxacillin Trovaﬂoxacin, Thiabendazole
Isoniazid with rifamipicin may be avoided. Isoniazid or
rifamipicin with ethambutol and quinolone can be used for
12 to 18 months. In Child Class C ethambutol, quinolone,
and one second line agent may be used for 12 to 18 months
[2, 14, 17–19].
Antifungal drugs like Ketocanozole and miconazole
though hepatotoxic can be used in patients with cirrhosis
but monitor drug concentration in serum is recommended.
Metronidazole reduce dose by 50% in patients with severe
cirrhosis and/or associated renal insuﬃciency. There is no
information of safe use of nitrofurntoin, chloramaphenicol,
sodium fusidate and pyrazinamide but they are poentially
toxic hence avoid their use in liver disease [14]( T a b l e s2
and 3).
3.Sedation,AnesthesiaandAnalgesiain
Patientswith LiverCirrhosis
Endoscopic procedures are often necessary in patients with
cirrhosis who may need sedation or short anesthesia. Benzo-
diazepines like midazolam administered in single dose have
minimal impact in patients with compensated cirrhosis.
Benzodiazepines can be cautiously used in decompensated
cirrhosis. Flumazenil can be used to reverse the eﬀect of
benzodiazepine. Fentanyl (opioid) elimination is near nor-
mal in cirrhotics and can be used for sedation. Patients
with opioid toxicity can be treated with nalaxone; propofol
is preferred to benzodiazepines or opioids for endoscopic
sedation for patients with decompensated cirrhosis due to
its short half life and lower risk of inducing encephalopathy.
In patients without extrahepatic high risk, the gastroen-
terologist directed propofol is safe. The adverse eﬀects of
propofol are hypotension, tachycardia, hypoventilation, and
prolongation of QT interval [1, 20–22].
4.AnestheticAgents
General Anesthesia can reduce the hepatic blood ﬂow result-
ing into decompensation. Volatile agents and halothane
shouldbeavoided.Thenewagentslikeisoﬂurane,desﬂurane
are not signiﬁcantly metabolized by the liver; hence, are safe.
Combination of agents like fentanyl may greatly reduce the
need of anesthetic agents. Propofol is also a good agent for
combination anesthesia [14, 23].
5. Analgesics
Pain management in cirrhosis is a challenging task as use of
analgesic agents is associated with severe complications like
gastrointestinal bleeding, hepatic encephalopathy, hepatore-
nal syndrome, and mortality. Nonsteroid anti-inﬂammatory
agents are contraindicated as they can induce GI bleed and
renalfailure.Opioidanalgesicshouldbeusedwithcautionas
it can precipitate encephalopathy. Acetaminophen at a dose
less than 2gm/day is a reasonably safe option. Patients with
cirrhosis having visceral or musculoskeletal pain should be
treated with acetaminophen less than 2-3gms/day [24, 25].
In case of inadequate pain relief, tramadol 25mg every 8
hours can be used. For intractable pain hydromorphone
orally or fentanyl topical patch can be used. Combination of
these drugs with tramadol should not be done. Neuropathic
pain can be treated with nortriptyline, desipramine, and
gabapentin, pregabalin with or without acetaminophen.
Analgesic choice in patients with cirrhosis should be individ-
ualizeddependingonetiologyofcirrhosis,nutritionalstatus,
adherence, renal function, liver transplant candidacy, and
drug-drug interaction [14, 20, 22].
6.Anticonvulsants
Phenytoin,Carbamazapin,andvalproatecanbehepatotoxic.
All the drugs can be used in patients with decompensated4 International Journal of Hepatology
liver disease with caution. The newer anticonvulsants like
lamotrigine, topiramate also need lowering of the dosage in
cirrhotic patients. Antidepressant, (selective serotonin reup-
take inhibitors) like ﬂuvoxamine, paroxetine, and ﬂuoxetine
need dose modiﬁcation in patients with cirrhosis [14].
Antiemetic metoclopramide and ondansetron require
signiﬁcant dose reduction in patients with cirrhosis. As
antiulcer agents proton pump inhibitors are preferred over
H2 receptor blockers but they still need half the dosage [14].
7. CardiovascularDrugTherapy
Patients of nonalcoholic steatosis-related cirrhosis have in-
creased incidence of dyslipidemia, hypertension, and coro-
nary artery disease. Drugs like labatolol and methyldopa can
cause severe hepatotoxicity and need frequent monitoring
and should be used only when there are no other choices.
Captopril, Amiodarone, and ticlopidine can cause hepato-
toxicity and should be used with caution. The details of dose
adjustments on alpha blockers, ACE inhibitors, angiotensin
II receptor antagonist, and other drugs used in cardiovascu-
lar diseases have been reviewed in the recent past [26]. Satins
appear to be remarkably safe in patients with liver cirrhosis
[27].
Drug-induced liver injury has been reported almost in
50% drugs in the physicians’ desk reference. More than 100
drugs are incriminated in causing fulminant hepatic failure.
The drugs that have been mentioned to be contraindicated
in the patients with liver disease are methotrexate, niacin,
Naltrexone, Metformin, Novastatin, Felbamate, Ticklopi-
dine, Clonazipam, Gemﬁbrizil, valproic acid, and estrogens
in the physicians’ desk reference, but some of them are
used in clinical practice under strict supervision. Metformin
can be used in patients with liver cirrhosis without renal
insuﬃciency. Other antidiabetics like second-generation sul-
fonylurea like Glipizide, Glimepride may be the drug of
choiceinpatientswithlivercirrhosis.Thiazolidinedionescan
cause drug hepatitis but can be used in reduced dosage with
strict monitoring [14, 15].
Inconclusionprescribingmedicinesinpatientswithliver
disease is a challenging task. There are no clear tests which
can identify altered drug metabolism in these patients. Med-
ications should be individualized depending upon various
factors. Surveillance using liver enzymes though recom-
mended routinely the use of INH can lead to acute liver fail-
ure despite the surveillance. The enhanced Nephrotoxicity of
radio contrast agents Aminoglycosides and NSAID may be a
more frequent and dangerous challenge than hepatotoxicity.
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